Potential use of craniosynostotic osteoprogenitors and bioactive scaffolds for bone engineering

Journal of Tissue Engineering and Regenerative Medicine

Volumn 1, Issue 3, 2007, Pages 199-210

  Santos Ruiz, L ^a   Mowatt, D J ^a,b   Marguerie, A ^g   Tukiainen, D ^c   Kellomaki M ^c   Tormala P ^c   Suokas, E ^d   Arstila, H ^e   Ashammakhi, N ^c,f   Ferretti, P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d Linvatec Biomaterials Ltd ^*  (Finland)

^e ÅBO AKADEMI UNIVERSITY   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g VASTox plc   (United Kingdom)

Author keywords

Bioabsorbable polymer; Bioactive glass; Craniosynostosis; FGFR; Human; Mouse; Osteoblast; Osteogenic

Indexed keywords

BIOACTIVE GLASS; BONE; CELL CULTURE; MESH GENERATION; SCAFFOLDS (BIOLOGY); SURGERY;

BIOABSORBABLE POLYMER; BIOACTIVE SCAFFOLD; BONE DIFFERENTIATION; CRANIAL BONE; CRANIOSYNOSTOSIS; FGFR; HUMAN; MOUSE; OSTEOGENIC; OSTEOPROGENITORS;

OSTEOBLASTS;

BIOLOGICAL MARKER; BIOMATERIAL;

ANIMAL; ARTICLE; BONE; CELL DIFFERENTIATION; CELL LINE; CRANIOFACIAL SYNOSTOSIS; CYTOLOGY; HUMAN; METABOLISM; METHODOLOGY; MOUSE; OSTEOBLAST; PATHOLOGY; SKULL; STEM CELL; TISSUE ENGINEERING; TISSUE SCAFFOLD;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; BONE AND BONES; CELL DIFFERENTIATION; CELL LINE; CRANIOSYNOSTOSES; HUMANS; MICE; OSTEOBLASTS; SKULL; STEM CELLS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 41949099078     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.26     Document Type: Article

References (26)

1. Burke D, Wilkes D, Blundell TL, Malcolm S. 1998; Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 23: 59.
2. Wilkie AO. 1997; Craniosynostosis: genes andmechanisms. Hum Mol Genet 6: 1647.
3. Panchal J, Uttchin V. 2003; Management of craniosynostosis. Plast Reconstr Surg 111: 2032.
4. Littlefield TR. 2004; Cranial remodeling devices: treatment of deformational plagiocephaly and postsurgical applications. Semin Pediatr Neurol 11: 268.
5. Chim H, Schantz JT. 2005; New frontiers in calvarial reconstruction: integrating computer-assisted design and tissue engineering in cranioplasty. Plast Reconstr Surg 116: 1726.
6. De Pollack C, Renier D, Hott M, Marie PJ. 1996; Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). J Bone Miner Res 11: 401.
7. Lomri A, Lemonnier J, Hott M, et al. 1998; Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 101: 1310.
8. Marie PJ, Debiais F, Hay E. 2002; Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol 17: 877.
9. Morriss-Kay GM, Iseki S, et al. 2001; Genetic control of the cell proliferation-differentiation balance in the developing skull vault: roles of fibroblast growth factor receptor signalling pathways. Novartis Found Symp 232: 102-116; discussion 116-121.
10. Lemonnier J, Delannoy P, Hott M, et al. 2000; The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res 256: 158.
11. Mansukhani A, Bellosta P, Sahni M, Basilico C. 2000; Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149: 1297.
12. Tanimoto Y, Yokozeki M, Hiura K, et al. 2004; A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279: 45926.
13. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. 1992; Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 7: 683.
14. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. 1983; In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96: 191.
15. Calvert JW, Chua WC, Gharibjanian NA, Dhar S, Evans GR. 2005; Osteoblastic phenotype expression of MC3T3-E1 cells cultured on polymer surfaces. Plast Reconstr Surg 116: 567.
16. Chen VJ, Smith LA, Ma PX. 2006; Bone regeneration on computer-designed nanofibrous scaffolds. Biomaterials 27: 3973.
17. Oldridge M, Wilkie AO, Slaney SF, et al. 1995; Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum Mol Genet 4: 1077.
18. Burg KJ, Porter S, Kellam JF. 2000; Biomaterial developments for bone tissue engineering. Biomaterials 21: 2347.
19. Yuan H, de Bruijn JD, Zhang X, et al. 2001; Bone induction by porous glass ceramic made from Bioglass (45S5). J BiomedMater Res 58: 270.
20. Lemonnier J, Hay E, Delannoy P, et al. 2001; Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J Bone Miner Res 16: 832.
21. Kaabeche K, Guenou H, Bouvard D, et al. 2005; Cbl-mediated ubiquitination of alpha5 integrin subunit mediates fibronectindependent osteoblast detachment and apoptosis induced by FGFR2 activation. J Cell Sci 118: 1223.
22. Debiais F, Lemonnier J, Hay E, et al. 2001; Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 81: 68.
23. Ashammakhi N, Renier D, Arnaud E, et al. 2004; Successful use of biosorb osteofixation devices in 165 cranial and maxillofacial cases: a multicenter report. J Craniofac Surg 15: 692.
24. YangXB, RoachHI, ClarkeNM, et al. 2001; Human osteoprogenitor growth and differentiation on synthetic biodegradable structures after surface modification. Bone 29: 523.
25. Lu HH, El-Amin SF, Scott KD, Laurencin CT. 2003; Threedimensional, bioactive, biodegradable, polymer-bioactive glass composite scaffolds with improved mechanical properties support collagen synthesis and mineralization of human osteoblast-like cells in vitro. J BiomedMater Res A 64: 465.
26. Ruhe PQ, Hedberg-Dirk EL, Padron NT, et al. 2006; Porous poly(DL-lactic-co-glycolic acid)/calcium phosphate cement composite for reconstruction of bone defects. Tissue Eng 12: 789.